Spruce Biosciences
SPRB
37 hedge funds and large institutions have $8.61M invested in Spruce Biosciences in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 18 closing their positions.
113% more call options, than puts
Call options by funds: $66K | Put options by funds: $31K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less funds holding
Funds holding: 49 → 37 (-12)
39% less capital invested
Capital invested by funds: $14.1M → $8.61M (-$5.51M)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
67% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$714K |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
+$283K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$116K |
| 4 |
6CM
683 Capital Management
New York
|
+$101K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aisling Capital Management
New York
|
-$948K |
| 2 |
SCM
Superstring Capital Management
New York
|
-$259K |
| 3 |
ACM
Altium Capital Management
New York
|
-$242K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$199K |
| 5 |
AIC
AWM Investment Company
New York
|
-$157K |
SPRB Hedge Fund Activity: Q2 2024 in Review
37 of the 6,930 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2024, worth a combined $8.61M — down 39% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of SPRB and 6 opened new positions — a net loss of 12 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Acadian Asset Management, adding an estimated $714K. The largest seller was Aisling Capital Management, exiting entirely with an estimated $948K sold.
- 37 institutional investors held Spruce Biosciences (SPRB) as of Q2 2024, down from 49 in Q1 2024.
- Funds reported $8.61M of Spruce Biosciences stock for Q2 2024, down 39% quarter-over-quarter.
- 6 funds opened new Spruce Biosciences positions in Q2 2024 and 18 closed out, a net change of -12 holders.
- The largest Spruce Biosciences buyer in Q2 2024 was Acadian Asset Management, an estimated $714K added.
- The largest Spruce Biosciences seller in Q2 2024 was Aisling Capital Management, an estimated $948K sold.
Based on aggregated 13F filings for Q2 2024.